John Clarke represents clients in complex litigation and internal investigations involving financial institutions, securities and financial instruments, structured transactions, accounting issues and corporate governance disputes. He also represents clients in a variety of litigation matters involving the antitrust and bankruptcy laws. He has significant experience in litigation involving failed bank receiverships and holding company bankruptcy cases. He is a frequent speaker and writer on issues involving financial institutions, corporate governance and the federal securities laws. He is the immediate past chairman of the Banking Law Committee of the Association of the Bar of the City of New York.
John's experience includes:
- Representing the underwriters in obtaining dismissal of a securities class action alleging '33 Act violations in the offering documents for trust preferred securities issued by a regional bank holding company
- Representing the underwriters in two pending securities class actions alleging '33 Act violations with respect to three separate securities offerings by a prominent New York-based insurance company
- Representing the former chief executive officer of a reinsurance company in a securities class action and SEC enforcement action concerning accounting for a finite reinsurance transaction
- Representing the underwriters in obtaining the dismissal of a securities class action alleging '33 Act violations in connection with the initial public offering of a company in the alternative energy industry
- Representing several outside directors of a government sponsored enterprise in obtaining the dismissal of securities and stockholder derivative litigation arising from an investigation by the Office of Federal Housing Enterprise Oversight and a subsequent financial restatement
- Representing the outside directors of a bank holding company based in Puerto Rico in consolidated stockholder derivative litigation and related matters arising from a financial restatement
- Representing a biotechnology firm in successfully defending a securities class action concerning the circumstances surrounding its announcement that the FDA had refused to accept for filing its application for regulatory approval of a groundbreaking cancer therapy
University of Virginia (1990) J.D.
Dartmouth College (1987) A.B.